Johnson & Johnson scientist details cyclization push behind targeted oral peptides

The wire

1. 01A J&J pharmacokinetics lead describes modeling binding sites in 3D, docking peptides for fit, then cyclizing and substituting amino acids to make molecules resistant to GI degradation.
2. 02The piece distinguishes regulated targeted oral peptides from unregulated peptide products sold by wellness clinics and online retailers on performance and inflammation claims.
3. 03No specific candidate, trial data or timeline is given; the argument that low absorbed doses reduce off-target risk is presented as developer reasoning rather than demonstrated outcomes.

From the source

Targeted oral peptides could reshape how precision prescription medicines reach patients

The challenge is no longer simply making peptide drugs that patients can swallow. It’s getting them to the right place in the body, in sufficient quantities, to do their job. Although a small number of peptide medicines are already available as pills, most candidates still face formidable barriers to oral delivery. New approaches to peptide design and drug delivery are testing how far those limits